

For: Journal of Frailty and Aging

**Exploratory functional and quality of life outcomes with daily consumption of the ketone ester bis-octanoyl (R)-1,3-butanediol in healthy older adults: a randomized, parallel arm, double-blind, placebo-controlled study**

**Brianna J Stubbs<sup>1\*</sup>, Elizabeth B Stephens<sup>1</sup>, Chatura Senadheera<sup>1</sup>, Stephanie Roa Diaz<sup>1</sup>, Sawyer Peralta<sup>1</sup>, Laura Alexander<sup>1</sup>, Wendie Silverman-Martin<sup>1</sup>, Jamie Kurtzig<sup>1</sup>, B. Ashen Fernando<sup>2</sup>, James T Yurkovich<sup>1,2</sup>, Thelma Y Garcia<sup>1</sup>, Michi Yukawa<sup>3</sup>, Jennifer Morris<sup>3</sup>, James B Johnson<sup>4</sup>, John C Newman<sup>1,5</sup>**

<sup>1</sup> Buck Institute for Research on Aging, Novato, CA, USA;

<sup>2</sup> Phenome Health, Seattle, WA, USA.

<sup>3</sup> Veteran's Affairs Medical Center, San Francisco, CA, USA;

<sup>4</sup> Independent Researcher, Greenbrae, CA, USA

<sup>5</sup> Division of Geriatrics, University of California, San Francisco, CA, USA.

SHORT TITLE: Ketone ester functional effects in older adults

\* Correspondence: Dr Brianna J. Stubbs: [bstubbs@buckinstitute.org](mailto:bstubbs@buckinstitute.org) ;

Dr John C. Newman [jnewman@buckinstitute.org](mailto:jnewman@buckinstitute.org)

Clinicaltrials.gov registration number: NCT05585762

Current protocol version number and date: version 1.3, approved on 16<sup>th</sup> October 2023

## 1 Abbreviations

1-RM	1 Repetition Maximum
ADL	Activities of Daily Living
AEs	Adverse Events
BDO	(R)-1,3-butanediol
BH-BD	Bis-hexanoyl (R)-1,3-butanediol
BHB	Beta-hydroxybutyrate
BMI	Body Mass Index
BO-BD	Bis-octanoyl (R)-1,3-butanediol
BTQ	Beverage Tolerability Questionnaire
CSHA	Canadian Study of Health and Aging
CRF	Case Report Form
DSST	Digit Symbol Substitution Test
IADL	Instrumental Activities of Daily Living
ITT	Intention to treat
KEs	Ketone Esters
MoCA	Montreal Cognitive Assessment
PLA	Placebo
PP	Per protocol
QoL	Quality of Life
SASP	Senescence-associated Secretory Phenotype
SPPB	Short Physical Performance Battery

2

3

## 4 **Abstract**

5 **Background:** Ketone bodies are metabolites produced during fasting or on a ketogenic diet  
6 that have pleiotropic effects on the inflammatory and metabolic aging pathways underpinning  
7 frailty in *in vivo* models. Ketone esters (KEs) are compounds that induce hyperketonemia  
8 without dietary changes and that may impact physical and cognitive function in young adults.

9 The functional effects of KEs have not been studied in older adults.

10 **Objectives:** Our long-term goal is to examine if KEs modulate aging biology mechanisms  
11 and clinical outcomes relevant to frailty in older adults. Here, we report the exploratory  
12 functional and quality-of-life outcome measures collected during a 12-week safety and  
13 tolerability study of KE (NCT05585762).

14 **Design:** Randomized, placebo-controlled, double-blinded, parallel-group, pilot trial of 12-  
15 weeks of daily KE ingestion.

16 **Setting:** The Clinical Research Unit at the Buck Institute for Research on Aging, California.

17 **Participants:** Community-dwelling older adults ( $\geq 65$  years), independent in activities of  
18 daily living, with no unstable acute medical conditions (n = 30).

19 **Intervention:** Subjects were randomly allocated (1:1) to consume 25 g daily of either KE  
20 (bis-octanoyl (R)-1,3-butanediol) or a taste, appearance, and calorie-matched placebo (PLA)  
21 containing canola oil.

22 **Measurements:** Longitudinal change in physical function, cognitive function and quality of  
23 life were assessed as exploratory outcomes in n = 23 completers (n = 11 PLA, n = 12 KE). A  
24 composite functional outcome to describe the vigor-frailty continuum was calculated. Heart  
25 rate and activity was measured throughout the study using digital wearables.

26 **Results:** There were no statistically significant longitudinal differences between groups in  
27 exploratory functional, activity-based or quality of life outcomes.

28 **Conclusion:** Daily ingestion of 25 g of KE did not affect exploratory functional or quality-  
29 of-life end points in this pilot cohort of healthy older adults. Future work will address these  
30 endpoints as primary and secondary outcomes in a larger trial of pre-frail older adults.

31 **Word Count: 299 (300 limit)**

32 **Keywords:** ketones, ketone ester, ketone di-ester, BO-BD, exogenous ketone, beta-  
33 hydroxybutyrate, frailty, physical function, strength, cognition, quality of life, geroscience

## 34 **Introduction**

35 The Geroscience Hypothesis, though yet untested in clinical trials, postulates that  
36 intervening in common aging biological mechanisms could mitigate or prevent various  
37 chronic age-related diseases as well as geriatric syndromes such as frailty (1). Frailty  
38 syndrome, characterized by diminished physiological reserves and heightened susceptibility to  
39 adverse health stressors, posing a significant risk for disability, institutionalization, and  
40 mortality (2). The prevalence of frailty escalates with age, with around 15% of adults over 65  
41 years old in the United States meeting one standard definition (3). Although the  
42 pathophysiology of frailty is multi-system and poorly elucidated, it is believed to encompass  
43 deficits in cellular energy production, chronic inflammation, and immune dysfunction (4, 5) –  
44 all of which also comprise geroscience molecular mechanisms commonly recognized as the  
45 "Hallmarks of Aging" (6). Presently, specific molecular therapies for frailty remain elusive,  
46 although interventions such as exercise programs, specialized geriatric care models, and  
47 nutritional strategies have shown the most promise in modulating the frailty phenotype and its  
48 sequelae (7).

49 A challenge in interventional studies of frailty is the choice of a primary outcome to  
50 capture clinically meaningful changes in function, especially as many outcomes focus on the  
51 frailest population, and poorly discriminate among those 'not frail'. Recently, Newman *et al.*,  
52 (8) used a large (n = ~900), well-characterized older adult population to develop a four-item  
53 continuous composite score (comprising digit symbol substitution, leg power, peak oxygen  
54 consumption and fatigability) that better captures the spectrum of function from vigorous to  
55 frail. The score was strongly associated with age, with lower scores predicting functional  
56 limitation (8). Such composite scores both increase the chance of detecting intervention-driven  
57 differences in higher functioning people and avoid the selection of a single arbitrary outcome

58 for a complex, multi-factorial condition such as frailty and pleiotropic interventions such as  
59 diet or exercise.

60 An increasing number of studies have explored the impact of dietary restriction and  
61 fasting on aging biology in animal models (9) and humans (e.g., CALERIE (10), HALLO-P  
62 (NCT05424042)). One key shared feature of dietary restriction and fasting is the presence of  
63 ketone bodies, notably beta-hydroxybutyrate (BHB), synthesized in the liver during fasting or  
64 carbohydrate restriction. The primary role of BHB is to provide an alternative energy source to  
65 various tissues, including the brain, muscle, and heart. The energetic and molecular signaling  
66 activities of ketone bodies, including improving mitochondrial function and regulating  
67 inflammatory activation, support a mechanistic role in modulating aging and may be directly  
68 relevant to frailty (11). Prior studies have demonstrated the potential of increasing circulating  
69 ketone concentrations in extending healthy lifespan and ameliorating age-related functional  
70 decline in animal models (12, 13).

71 Ketone esters (KEs), such as bis-octanoyl (R)-1,3-butanediol, are examples of exogenous  
72 ketones, small molecules that deliver ketone bodies without other dietary changes (14, 15).  
73 KEs are hydrolyzed in the gut to release ketogenic precursors, which are then metabolized in  
74 the liver to release ketone bodies (16). In preclinical models, ketone bodies and KEs attenuate  
75 muscle atrophy through anticatabolic signaling activities (17), improve heart function in age-  
76 related heart failure (18, 19), and promote healthy function of T cell subpopulations (20, 21).  
77 Clinically demonstrated effects of acute KE administration range from blood glucose control  
78 (22, 23) to physical (24, 25), cognitive (26, 27), immune (28), and cardiovascular (27, 29)  
79 function in younger adult populations under the age of 65. These observations have led to our  
80 central hypothesis, that ketone bodies delivered through KEs may ameliorate the frailty  
81 syndrome through multi-system energetic and signaling activities that improve metabolic and


82 immune function. To date, there are no published studies describing the effects of KE on  
83 functional outcomes in an aging population.

84 To begin addressing this gap, and laying the foundation for future work testing the KE in  
85 a pre-frail and frail population (NIH funding ID: **1R01AG081226-01**), we undertook a 12-  
86 week randomized, placebo-controlled, double-blinded, parallel-group pilot clinical trial with  
87 the primary objective of generating the first long-term safety and tolerance data for KEs in an  
88 independent living, generally healthy population of older adults. Here we report data  
89 describing our exploratory aging-focused functional endpoints. We also calculated a four-item  
90 composite outcome score based on the work of *Newman et al (8)* to investigate functional  
91 changes on a continuum from vigorous to frail. Based on the positive data of short-term KE  
92 use in younger adults, we hypothesized that 12-weeks of KE consumption would improve  
93 functional outcomes in our older adult population.

## 94 Methods

### 95 Study Design Overview

96 Healthy older adults  $\geq 65$  years of age ( $n = 30$ ) took part in this randomized, 12-week  
97 randomized, placebo-controlled, double-blinded, parallel-group, pilot clinical trial (Figure 1).  
98 The full study design was powered to determine tolerance and safety and has been previously  
99 described (30, 31). The study included single-administration kinetics visits prior to starting  
100 and after completing the main 12-week protocol, results of which are reported separately (32).  
101 Physical, cognitive, and quality of life (QoL) exploratory outcomes were measured at week 0  
102 and week 12. Participants arrived at these visits fasted for blood draws, then were provided  
103 with a snack and, if desired, coffee or tea prior to beginning functional testing. Wrist based  
104 health and fitness monitors were distributed at the first kinetics visit (at least 7 days before  
105 baseline) and were worn continuously until the final visit. The study was approved by Advarra  
106 IRB on September 28<sup>th</sup> 2022 (Pro00065464). The first subject was randomized on January 31<sup>st</sup>  
107 2023 and the final subject completed the trial on January 17<sup>th</sup> 2024, which ended the study.  
108 The study was conducted in accordance with the 2013 Declaration of Helsinki.



109  
110 **Figure 1:** Study schematic showing the schedule of visits and assessments described in this  
111 article. **Abbreviations:** KE, ketone ester; QoL, quality of life. Created using BioRender.com  
112

### 113 Participants



114 Participants were community dwelling older adults ( $\geq 65$  years of age), independent in  
115 activities of daily living and in stable health. The full inclusion and exclusion criteria are listed  
116 in the **Supplemental Information**. Decisions on eligibility were made by an independent  
117 medical officer to ensure allocation was concealed, and eligible participants were randomized  
118 by the study team based on a statistician-generated block allocation sequence (block size 4,  
119 intended to equally randomize male and female participants). The flow of study participants is  
120 illustrated in the CONSORT diagram (**Supplementary Figure 1**). Sample size was  
121 determined *a priori* based on the primary outcome of the study, which was tolerance of the KE  
122 beverage (30), and feasibility of this pilot.

### 123 ***Study Beverages***

124 The study KE beverage was a tropical-flavored beverage containing the KE bis-octanoyl (R)-  
125 1,3-butanediol (Cognitive Switch, BHB Therapeutics Ltd, Dublin, IRE). Each bottle was 75  
126 mL and contained 25 g of KE. Participants were instructed to consume the study beverage at  
127 home daily for 12 weeks within 5 minutes of their first meal of the day. Half of a bottle (12.5  
128 g KE) was consumed daily during week 1, and a full bottle (25 g KE) for the remainder of the  
129 study. The placebo used in the study was custom manufactured by BHB Therapeutics. In the  
130 placebo the KE was replaced with a non-ketogenic canola oil and matched for volume,  
131 appearance, flavor and calories. Nutritional facts for study beverages are shown in  
132 **Supplemental Table 2**. Beverages were provided as single serving bottles and labeled with  
133 the coded group allocation. All personnel involved with the data collection, subject  
134 assessment, analysis, and interpretation were blinded to the identity of the intervention  
135 assigned to participants, but not the allocation.

### 136 ***Frailty Indices***

137 All frailty indices were evaluated by self-report during an interview in the screening and final  
138 visits as follows: Katz Index of Independence in Activities of Daily Living (Katz ADL) (33),

139 Lawton Instrumental Activities of Daily Living (Lawton IADL) (34), and Canadian Study of  
140 Health and Aging (CSHA) Clinical Frailty Scale (CFS) (35, 36).

#### 141 ***Physical Function***

142 Physical function measures were collected at the baseline and final visits as follows: 1  
143 repetition maximum (1-RM) leg press strength, 70% of 1-RM leg press fatiguability (both  
144 using Matrix Versa, Matrix Fitness, Cottage Grove, USA), Short Physical Performance  
145 Battery (SPPB), 4 m gait speed (as part of the SPPB), 6-minute walk test, grip strength, and  
146 actigraphy (FitBit Inspire 2, FitBit, San Francisco, USA). Subjects were familiarized with the  
147 1-RM equipment during the first kinetics visit.

#### 148 **One Repetition Maximum (1-RM) Leg Press Strength**

149 Subjects were instructed on proper positioning and form on the seated leg press machine. They  
150 were positioned with their back straight and against the back rest, their feet on the footplate so  
151 that knee and hip angles were approximately 90° and the weight sled was adjusted accordingly.  
152 Foot position and sled position were replicated for both visits. The Rating of Perceived  
153 Exertion (RPE) Category-Ratio Scale was used to measure effort (37), RPE of 9-10 was the  
154 target. First, subjects performed 5 - 6 unweighted repetitions as familiarization and to correct  
155 positioning or form. Then, subjects completed a decreasing number of repetitions (starting  
156 repetitions = 6 - 7) at a set weight (starting weight = 50% body weight) and rated their  
157 exertion after each set. Weight increased and number of repetitions decreased incrementally  
158 until the target RPE was achieved and the participant could only perform one repetition.  
159 Standardized rest was timed between each set and participants were verbally encouraged  
160 throughout the test.

#### 161 **Leg Press Fatiguability**

162 Leg press fatiguability was performed after the 1-RM leg press after at least 5 minutes of rest.  
163 Positioning was replicated from the 1-RM leg press strength test. Weight was set to 70% of

164 the 1-RM and subjects were instructed to complete as many repetitions as possible whilst  
165 maintaining proper form and a consistent cadence. Improper form was corrected once, the test  
166 was ended if a second correction was required. Exertion was rated using the RPE Category-  
167 Ratio Scale (37) immediately following completion. Participants were given verbal  
168 encouragement throughout the test.

### 169 **Short Physical Performance Battery (SPPB)**

170 The SPPB includes several short tests to evaluate lower extremity function, including  
171 measures of standing balance, 4-meter gait speed, and ability to rise from a chair 5 times, and  
172 was administered according to standard instructions (38).

### 173 **6-Minute Walk Test**

174 A 10-meter-long course was measured and marked with tape at each meter interval and a cone  
175 at each end. Subjects were instructed to walk briskly from cone to cone, rounding the cones to  
176 invert direction, for 6 minutes. Subjects were provided with standard encouragement  
177 throughout. Before walking began and immediately following completion, subjects measured  
178 their exertion and breathing difficulty using the RPE Category-Ratio Scale and Modified Borg  
179 Dyspnea Scale (37). After 6 minutes, subjects stopped in place, and partial laps were recorded.

### 180 **Grip Strength**

181 Grip strength was measured using a Jamar Hydraulic Hand Dynamometer (Jamar,  
182 Warrenville, IL, USA). Participants were sat in an armed chair and instructed to rest their arms  
183 on the arm rests with their elbow at a 90° angle. The dynamometer handgrip was adjusted to a  
184 setting comfortable for the subject, and a submaximal practice test was performed for  
185 familiarization. Three trials were performed per hand, and hands were alternated between  
186 trials. Measurements were recorded in kgs and rounded to the nearest 2 kg.

### 187 ***Health and Fitness Tracker***

188 Wrist health and fitness trackers were dispensed at the kinetics visit at least 7 days before the  
189 baseline visit. Subjects were instructed to wear the device throughout the 12-week trial, except  
190 for charging. The device was used to record heart rate, steps, sleep (total time asleep and sleep  
191 efficiency), and activity (sedentary, lightly active, moderately active, and very active minutes).

### 192 *Cognitive Function*

193 Cognitive function measures were collected at the baseline and final visits as follows:

194 Montreal Cognitive Assessment (MoCA), Trails Test A and B, and Digit Symbol Substitution  
195 Test (DSST). All cognitive function tests were conducted by trained study staff according to  
196 standard protocols, in a private, quiet room. The MoCA was scored by a study physician.

### 197 *Quality of Life*

198 QoL measures were collected via self-rated questionnaire at the baseline and final visits as  
199 follows: Geriatric Depression Scale (GDS), Pittsburgh Sleep Quality Index (PSQI), 36-Item  
200 Short Form Health Survey (SF-36, Version 1, Rand), Profile of Mood States—Short Form  
201 (POMS-SF), sexual quality of life questionnaire (SQoL), Pittsburgh Fatigability Scale (PFS).

202 All quality-of-life questionnaires were conducted on paper with pen in a private room.

203 Questionnaires were scored by trained study staff.

### 204 *General Statistical Design*

205 Statistical analysis was carried out using Prism 10, except for actigraphy analysis, which was  
206 carried out in R and Python. Data is shown as mean (standard deviation), unless otherwise  
207 specified. Significance was set at  $p < 0.05$ . P values are not adjusted for multiple comparisons  
208 given the exploratory nature of these analyses.

209 To analyze individual physical, cognitive and QoL outcomes, we firstly confirmed there were  
210 no differences at baseline between intervention groups; raw baseline values for KE and PLA  
211 group were compared using an unpaired t-test or a Mann-Whitney Test, as appropriate. If  
212 there was no significant difference between groups at baseline, a Week 0 to 12 change value

213 was calculated for each outcome in each individual who completed the study per protocol. The  
214 between-group difference in change value was then compared using an unpaired t-test or a  
215 Mann-Whitney Test, as appropriate.

### 216 ***Composite Frailty Score***

217 A composite frailty score was calculated based on the rationale of Newman *et al* (8). We  
218 included four outcomes: leg strength (1 rep max leg press weight), endurance (6 minute walk  
219 test), speed (digit symbol substitution) and perceived Fatigability (Pittsburgh Fatigability  
220 Scale – Physical). A z-score for each individual at baseline was calculated, and a z-score for  
221 the pre- to post- change in per protocol subjects was calculated using the standard deviation of  
222 the pooled baseline values. Z-scores were calculated as sex-specific. The z-scores of the four  
223 items of interest were averaged to give the final composite score. A simple linear regression  
224 was calculated for the the baseline composite score vs. age and the pre- to post- change in  
225 composite score vs. age.

### 226 ***Health and Fitness Tracker Data Analysis***

227 Health and fitness tracker data was analyzed separately for each variable of interest, data was  
228 compiled for all per protocol subjects and duplicates were removed. Heart rate data was  
229 processed by filtering out low confidence measurements (confidence < 2). We determined  
230 sleep timing through the Fitbit’s sleep staging, and mapped these time windows with the heart  
231 rate data to determine sleeping heart rate. We then calculated the sleeping heart rate (SHR) to  
232 be the mean value over each night-time sleep period for each individual. Time asleep was  
233 determined by the Ftibit’s sleep staging, excluding all daytime naps (one dataset was missing).  
234 Minutes of sedentary, light, moderate and vigorous activity was determined through Fitbit’s  
235 Active Minutes function that combines heart rate and movement data. Total minutes of each  
236 activity type per day was calculated by adding all data points per date. All data was analyzed  
237 by plotting the mean of each value per allocation, with bands generated using the standard

238 error. Additional figures plotted each individual's time course with an aggregate mean value  
239 per allocation. These data were analyzed using R 4.3.1 and Python.

240

241 **Results**

242 *Participants and completion*

243 A total of 30 participants were randomized (mean age (range), Male n = 15; age = 76.5 y (65  
244 – 90); mean BMI (range) = 25.2 (19.9 – 32.7); median Katz ADL (range) = 6 (5-6), median  
245 Lawton IADL (range) = 8 (8-8), median CSHA Frailty Score (range)= 1 (1 – 3)). Full  
246 participant anthropometric characteristics and frailty indices at baseline are shown in

247 **Supplemental Table 1.**


248 Subject disposition is shown in a CONSORT diagram (**Supplemental Figure 1**). Briefly, 23  
249 subjects completed the 12-week protocol (the per-protocol population), 1 participant  
250 completed the acute kinetics visit but did not start the main study, without giving a reason,  
251 and 6 participants dropped out after Day 0 and did not complete the full protocol; repeat  
252 functional data was not available for subjects who did not start or finish the study. Adherence  
253 with consumption of the study products for the per protocol population was high, with n = 15  
254 reporting 100% adherence and a range of 94 – 99 % for the remaining 8 participants who  
255 completed the study, based on study logs and returned bottles.

256

257 *Frailty Indices and Frailty-Vigor Composite*

258 No subjects experienced a change in Katz ADL or Lawton IADL scores after the  
259 intervention. The CSHA Frailty Score was changed by one point in n = 3 subjects (PLA = 2,  
260 one increase, one decrease, KE = 1, increase). There were no significant differences between  
261 groups in pre- to post- change in any of the individual items included in the composite score  
262 (**Figure 2 A-D**): 1 rep max leg pres (KE = -0.8 (13.4) kg, PLA = 0.9 (10.9) kg, p = 0.834),  
263 Six Minute Walk Test (KE = 42.1 (48.1) m; PLA = 30.9 (38.8) m, p = 0.705), Digit Symbol  
264 Substitution Task (correct) (KE = 2.4 (4.6); PLA = 2.6 (4.0), p = 0.706), Pittsburgh  
265 Fatigability Scale (Physical) (KE = 0.1 (3.6); PLA = -1.6 (5.2), p = 0.711). When the items

266 were converted to z-scores and combined into the 4-item composite outcome, there was no  
267 significant difference between groups (KE = 0.21 (0.25); PLA = 0.17 (0.23),  $p = 0.833$ ,  
268 **Figure 2E**). The baseline composite score trended down with increasing age ( $F = 2.037$ ;  $df =$   
269  $1, 27$ ;  $P = 0.165$ ;  $R^2 = 0.07$ ; **Figure 2F**), and the change in composite score over the 12 week  
270 intervention was not related to the age of the subject ( $F = 0.002$ ;  $df = 1, 21$ ;  $P = 0.967$ ;  $R^2 =$   
271  $8.26 \times 10^{-5}$ ); **Figure 2G**).



272

273 **Figure 2:** Change in four functional outcomes from pre- to post- 12 weeks of daily  
274 consumption of ketone ester or placebo in  $n = 23$  healthy older adult. **A:** 1 repmax leg press,  
275 **B:** six minute walk test, **C:** digit symbol substitution task, **D** Pittsburgh Fatigability Scale.  
276 Change in the composite score resulting from the combination of these four outcomes (**E**),  
277 and characteristics of the composite score (**F,G**). **Abbreviations:** KE, ketone ester; PLA,  
278 placebo; 6MWT, six minute walk test; DSST, digit symbol substitution task, PFS, Pittsburgh  
279 Fatigability Scale. Y-axes are oriented so higher is better in all panels.

280

### 281 *Physical function*

282 There were no significant differences between intervention groups in the longitudinal change  
283 in the remaining physical function outcomes (**Figure 3 A-C**): grip strength (KE = -1 (4.8) kg;  
284 PLA = 0.6 (6.0) kg,  $p = 0.728$ ), Short Physical Performance Battery (KE = 0.0 (0.4); PLA =



285 0.4 (0.5),  $p = 0.197$ ) or leg press reps to fatigue at 70% of maximal weight (KE = -0.7 (7.3);

286 PLA = -1.1 (5.2),  $p = 0.982$ ).

287


### 288 *Cognitive function*

289 There were no significant differences between intervention groups in the longitudinal change

290 in the remaining cognitive function outcomes (**Figure 3D-E**): Trails A (KE = -5.8 (11.8) s;

291 PLA = -1.6 (12.1) s,  $p = 0.422$ ), Trails B (KE = -7.8 (30.5) s; PLA = -1.4 (16.3) s,  $p > 0.999$ )

292 or Montreal Cognitive Assessment (KE = 1.7 (2.0); PLA = 0.1 (2.1),  $p = 0.068$ ).



293

294 **Figure 3:** Changes in physical and cognitive function outcomes from pre- to post- 12 weeks  
295 of daily consumption of ketone ester or placebo in  $n = 23$  healthy older adults. **A:** grip  
296 strength, **B:** short physical performance battery, **C:** leg press reps to fatigue at 70% maximal  
297 weight, **D:** Trails A, **E:** Trails B, **F:** Montreal Cognitive Assessment. **Abbreviations:** KE,

298 ketone ester; PLA, placebo; MoCA, Montreal Cognitive Assessment; SPBB, Short Physical  
 299 Performance Battery. Y-axes are oriented so higher is better in all panels.  
 300

301 *Quality of life*

302 There were no differences between study groups in the longitudinal change in any of the  
 303 subdomains or global summary scores (where appropriate) of the Profile of Mood States, SF-  
 304 36, Geriatric Depression Scale, Sexual Quality of Life questionnaire, or the Pittsburgh  
 305 Fatigability Scale (**Table 1**). Sleep, assessed by the Pittsburgh Sleep Quality Index (PSQI)  
 306 demonstrated a worsening in subjective sleep efficiency in the KE group (KE = 0.8 (1.6);  
 307 PLA = -0.5 (1.1),  $p = 0.058$ ) and a significant worsening of the global PSQI index in the KE  
 308 group (KE = 1.8 (2.6); PLA = -0.3 (2.3),  $p = 0.047$ ) (**Table 1**).

309

310 **Table 1:** Summary of the pre- post- intervention change in quality of life outcomes in .  
 311 **Abbreviations:** GDS, Geriatric Depression Scale; PFS, Pittsburgh Fatigability  
 312 Questionnaire;POMS, Profile of Mood States; PSQI, Pittsburgh Sleep Quality Index; SD,  
 313 Standard Deviation; SF-36, Short Form 36; SQoL, Sexual Quality of Life. † = some subjects  
 314 declined to complete the SQoL, \* =  $p < 0.05$ .

Instrument	Sub-domain	PLA			KE			P Value
		Mean Change	SD	N	Mean Change	SD	N	
POMS	Anger- hostility	-1.64	5.43	11	-0.67	2.42	12	0.650
	Confusion - bewilderment	-0.82	2.71	11	1.33	3.14	12	0.135
	Depression-dejection	-0.91	2.07	11	-0.17	4.55	12	0.415
	Fatigue - inertia	-2.27	4.22	11	-0.75	6.66	12	0.727
	Tension-anxiety	-0.73	3.44	11	1.75	5.22	12	0.211
	Vigor-activity	-1.18	8.20	11	-0.50	6.19	12	0.774
	Friendliness	0.73	4.69	11	1.58	4.44	12	0.528
	TMD – Global Score	-1.45	4.20	11	0.50	4.42	12	0.292
SF-36	Physical Functioning	-1.36	4.52	11	-0.83	4.69	12	0.792
	Role functioning / physical	-6.82	19.66	11	-6.25	38.62	12	0.942
	Role functioning / emotional	0.06	14.76	11	5.56	19.25	12	0.739
	Energy/ fatigue	0.45	9.07	11	6.46	11.70	12	0.181
	Emotional Well-Being	1.09	6.95	11	-1.33	11.73	12	0.935
	Social Functioning	-1.14	3.77	11	0.00	15.99	12	0.876
	Pain	-4.32	14.88	11	-2.50	17.74	12	0.820
	General Health	0.46	9.99	11	-2.81	15.34	12	0.512
PSQI	Subjective Sleep Quality (/3)	0.00	0.63	11	0.42	0.67	12	0.180


	Sleep Latency (/3)	-0.09	0.94	11	-0.25	1.22	12	0.386
	Sleep Duration (/3)	0.09	0.30	11	0.25	0.75	12	0.409
	Habitual Sleep Efficiency (/3)	-0.45	1.13	11	0.75	1.54	12	0.058
	Set Disturbances (/3)	0.00	0.63	11	0.17	0.39	12	0.690
	Use of Sleeping Medication (/3)	0.09	0.54	11	0.42	0.67	12	0.329
	Daytime Dysfunction (/3)	0.09	0.30	11	0.08	0.51	12	>0.999999
	Global PSQI Score (/21)	<b>-0.27</b>	<b>2.33</b>	<b>11</b>	<b>1.83</b>	<b>2.59</b>	<b>12</b>	<b>*0.047</b>
	GDS	-0.09	0.83	11	0.33	1.30	12	0.638
	SQoL †							
	Female (/108)	2.50	3.32	4	0.00	5.00	3	0.600
	Male (/66)	-1.00	3.21	7	-5.86	5.64	7	0.154
	PFS							
	Physical (/50)	0.09	3.59	11	-1.64	5.22	11	0.711
	Mental (/50)	1.27	3.32	11	-0.18	3.16	11	0.296

315

### 316 *Health and Fitness Tracker*

317 We observed a qualitative difference in sleeping heart rate (SHR, the mean heart rate during  
 318 one sleep period; see **Methods**) trends between the KE and PLA groups, with the KE arm  
 319 showing a sustained elevation in SHR (**Figure 4A**). In contrast to the PSQI data indicating  
 320 lower subjective sleep quality with the KE, we did not see any differences in between groups  
 321 trend in sleep minutes (**Figure 4B**) or efficiency (**Supplemental Figures**). There were no  
 322 differences in steps (**Figure 4C**) or total active minutes (**Figure 4D, Supplemental Figures**)  
 323 between groups. For all measures, the small effect size of the cohort and the high inter-  
 324 individual variability prohibited any meaningful quantification of the difference between the  
 325 two arms.

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/) .



326

327

328

329

330

331

**Figure 4:** Data from wearable health and fitness trackers worn by study participants who completed the 12 week protocol, showing mean and standard error for A) sleeping heart rate, B) sleep minutes, C) daily steps, D) total active minutes for 7 days before baseline visit, and for the remaining 12 weeks of the study. Abbreviations: KE, ketone ester; PLA, placebo.

## 332 **Discussion**

333           The main finding of this exploratory analysis of the effects of 12 weeks of KE  
334 consumption on functional outcomes in a pilot study of healthy older adults was that, in  
335 contrast to our hypothesis, there were no statistically significant effects of the KE intervention  
336 on a composite score designed to capture the vigor-frailty continuum, or on individual items  
337 scoring physical or cognitive function, activity, resting heart rate or quality of life. However,  
338 this tolerability-focused pilot randomized controlled trial was not powered for functional  
339 outcomes, and enrolled non-frail, healthy older adults. As an example of an early-stage  
340 geroscience clinical trial, we discuss the rationale for intervention-specific outcome measures  
341 as well as the selection of common measures that broadly capture function in aging and  
342 represent a common toolbox for geroscience clinical trials (39, 40).

343           Ketone bodies are expected to benefit physical function via multiple distinct  
344 mechanisms. Firstly, ketones might act as an alternative energy substrate that directly  
345 improved working muscle efficiency (41). Secondly, there is a known acute effect of  
346 exogenous ketones on cardiac output and myocardial blood flow (42), which may indirectly  
347 facilitate physical function. Thirdly, ketones are known to be anticatabolic and may increase  
348 muscle protein synthesis and decrease muscle protein breakdown in the context of  
349 inflammatory stress (43, 44), feasibly such as that seen during age-related or frailty-related  
350 inflammation, which could preserve or increase muscle mass and function with longer term  
351 use. Some, but not all, studies that administered exogenous ketones to young athletes  
352 immediately prior to endurance exercise found functional improvements (24, 25). The only  
353 study of physical function with longer term exogenous ketone consumption found that KE  
354 could mitigate the performance decline and hormonal shifts triggered by ‘over-reaching’  
355 endurance training in young adults (45). Clinical evidence for a muscle sparing function of  
356 exogenous ketones is limited. Two studies used ketone infusions in healthy young men and  
357 found attenuated leucine oxidation and increased muscle protein synthesis (43), and a

358 decreased muscle protein breakdown in the context of an inflammatory stressor (44). A further  
359 study gave a ketone ester drink and found lowered post exercise AMPK phosphorylation and  
360 higher mTORC1 activation, suggesting greater protein synthetic potential (46). None of these  
361 studies investigated functional changes in muscle strength.

362 While this study is part of a program to test the long-term effects of chronic daily use  
363 of KE in frailty, these data from athletes suggest that other approaches might be fruitful to  
364 pursue in parallel. For example, the greatest performance gains might be acutely during  
365 ketosis, perhaps relevant to scheduling the use of ketones as rehabilitation or exercise  
366 adjuvants. A concurrent stressor might increase the effects from ketones. Heart failure or other  
367 medical problems associated with energetic stress might be seen as examples of such stressors,  
368 but a more benign stressor might be resistance training. A parallel can be drawn with dietary  
369 protein supplementation, which alone does not consistently improve muscle mass and function  
370 in older adults (47), but increases the efficacy of resistance training compared to a placebo  
371 (48, 49). Future work could address combinations of ketones, protein and resistance exercise  
372 to determine if there any synergistic effects of these strategies acutely and long-term.

373 The rationale for an effect of exogenous ketones on cognitive function is also  
374 multifactorial. Firstly, ketones act as an energy source in the brain and can mitigate the deficit  
375 in brain energetic needs that arises during age-related declines in glucose metabolism (50).  
376 Secondly, ketones increase brain blood flow which would improve delivery of substrates and  
377 oxygen (27, 51). Thirdly, ketones can trigger the release of neurotrophins, particularly brain  
378 derived neurotrophic factor (BDNF) (52). Key clinical examples include a 12-month study of  
379 two 15g daily servings of a ketogenic medium chain triglyceride, which found improved brain  
380 energy metabolism and cognition in adults with mild cognitive impairment (53), and a 14-day  
381 study of three 12 g daily servings of a ketone ester which found improved cerebral blood flow  
382 and elements of cognition in obese adults (27). As there is a strong biological mechanism and

383 both preclinical and clinical support for a neurocognitive effect of exogenous ketones,  
384 outcome measures relating to brain physiology and function will remain of keen interest in  
385 future work.

386         Whilst they are many steps removed from the underlying biological mechanisms and  
387 likely are influenced by multiple mechanisms, subjective self-assessment of quality of life is  
388 increasingly recognized as an important outcome in interventional geroscience trials that can  
389 distinguish functionally healthy and unhealthy aging (54). To this end, we included a range of  
390 validated quality of life questionnaires, notably the SF-36, which has been proposed as a  
391 leading quality of life assessment tool (54).

392         We did observe a decline in subjective sleep efficiency and overall sleep score in the  
393 KE population during the study, although there were no matching trends in sleep time or  
394 efficiency measured by our health and fitness tracker data. It is unclear if the trend for  
395 increased SHR in the KE group could have contributed to lower sleep quality; acutely  
396 increased heart rate following administration of exogenous ketones has been reported in some  
397 studies (29, 51, 55), but heart rate returns to basal values when plasma BHB falls (27, 56),  
398 although no data from a continuous wearble exists to our knowlege. Only one published study  
399 has investigated the interaction between exogenous ketones and sleep, finding that  
400 consumption of a ketone ester before bed, after high intensity exercise, improved sleep quality  
401 in young athletes (57). Our results indicated the opposite effect, although many contextual  
402 elements are different between studies, including KE timing, study population, and the  
403 addition of exercise as a stressor. Sleep is a critical component of health (58), and sleep  
404 quality generally declines with age (59), therefore future studies using KE in older adults  
405 should continue to monitor sleep quality, along with other quality of life domains to  
406 definitively elucidate any effects of KE.

407 We chose to explore the sensitivity of a composite score for vigor-frailty as it is  
408 increasingly appreciated that many gerotherapeutic strategies, such as BO-BD, could have  
409 pleiotropic and potentially modest effects across a variety of individual organ systems (e.g.,  
410 muscle strength, endurance, cognitive function) but have a clinically important overall effect  
411 on the whole person due to these integrated, potentially synergistic, multi-system effects (60).  
412 It should be noted that the use of a composite is not without downsides, as a study using a  
413 composite score might fail to capture substantial changes within just one domain if not  
414 statistically powered for that endpoint alone. Composite outcomes are increasingly used in  
415 geroscience focused studies and range from composites of death or disease onset (e.g.,  
416 Targeting Aging with Metformin - TAME), of blood and clinical biomarkers (e.g., in SGLT-2  
417 trials) or of functional endpoints (e.g., Intrinsic Capacity). Composite cardiovascular outcomes  
418 (e.g. Major Adverse Cardiovascular Events, MACE) are widely used in clinical trials (61).  
419 Given the frailty expertise of the SOMMA investigators, and the size and richness of the  
420 SOMMA dataset, we chose to adapt the SOMMA-derived composite vigor-to-frailty outcome  
421 using leg press weight rather than leg power, and 6-minute walk test distance instead of a  
422 direct  $VO_2$  max measurement as a measure of endurance, as this 6-minute walk is commonly  
423 used to estimate  $VO_2$  max (62). As we expected, our baseline composite score showed a trend  
424 of decreasing with age even in our small and functionally independent population. We did not  
425 see any difference in composite score between intervention groups, and importantly we did  
426 not see an age-effect on change in composite score. Overall, the data from this cohort provided  
427 an interesting opportunity to explore the implementation of a frailty focused composite  
428 outcome, which might have an increased likelihood of detecting any KE driven effects in  
429 future studies.

430 The strengths of this study include the free-living, pragmatic-inspired design (e.g.  
431 participants were instructed to maintain their usual diet and exercise habits) being highly



432 relevant for future uses of KE as a geroscience intervention, the high adherence observed, the  
433 equal enrollment of men and women, the average age (76 y) being well over the lower limit  
434 (65 y), and the close matching achieved between the KE and PLA beverage, although the  
435 findings should be interpreted with the context that the lipid-based PLA was not truly ‘inert’  
436 and thus does not offer a comparison to ‘no intervention’.

437         There were several limitations of this study, many of which were inherent to its  
438 design as a “first in older adults” early-stage geroscience clinical trial (60), and that we plan to  
439 address in our follow-up study. The primary goals of this pilot study were to fill key gaps in  
440 kinetics, tolerability, and safety in older adults that would unlock the ability to design  
441 function-focused clinical trials with KE in older adults. The 12-week study duration was  
442 selected conservatively due to the longest prior study of any KE in any population being only  
443 4 weeks, and the unknown feasibility and safety of the intervention in older adults. However,  
444 12 weeks is relatively short to expect detectable changes in functional outcomes which often  
445 take months or years to manifest. Furthermore, whilst the 25 g once daily serving size was  
446 selected based on the previous studies of BO-BD in young adults, and the absence of any data  
447 on any dose of KE in older adults, studies of other KE in young adults have used servings of  
448 up to 75 g daily split across three doses. Further increasing blood ketone concentrations or  
449 overall exposure time with larger or more frequent dosing may increase response. It is also  
450 important to note that several types of exogenous ketones and KEs exist, with known  
451 differences in physical characteristics and possibly also functional effects, therefore our results  
452 using BO-BD may not apply to all types of exogenous ketones. In addition, the optimal  
453 outcome measures for early-stage geroscience clinical trials have not been defined. There is  
454 clear advantage to using measures that are well validated and commonly used in large  
455 longitudinal studies, though some of these may be best suited to much longer multi-year  
456 studies. Many of these outcomes also have considerable inter-individual variability across

457 testing occasions, as well as training effects that limit repetition. Novel functional biomarkers  
458 may help bridge the gap between target engagement or kinetic outcomes (e.g. blood BHB  
459 levels) and clinically relevant, patient-centered, long-term functional outcomes. Notably, we  
460 chose to conduct all functional testing on days without KE consumption to focus on stable,  
461 sustained effects of KE rather than transient performance associated with acute ketosis (and to  
462 avoid confounding from the sequencing of study activities with respect to the peak of post-  
463 ingestion blood BHB concentrations). However, it is possible that ongoing ketosis is required  
464 for performance gains. Specific investigation will be required to answer this important  
465 question. Finally, the small sample size and relatively healthy and fit population, both  
466 determined by the primary study goals, were major limitations in our ability to detect a  
467 difference in these exploratory functional outcomes. We expect that a larger sample size, and a  
468 study population selected for increased vulnerability or with existing mild functional  
469 limitations would increase the likelihood of a detectable positive effect.

470 In conclusion, consuming the KE, BO-BD, daily for 12 weeks did not impact  
471 exploratory quality of life, physical or cognitive functional outcomes in this pilot cohort of  
472 healthy older adults. Future work using a larger cohort of pre-frail and early frail older adults  
473 will seek to definitively test if the hypothesized benefits of exogenous ketones will be  
474 detectable against a functionally limited baseline.

475

476 **Sources of Funding, Author Declarations and Conflict Management:**

477 Funding for the study was provided by philanthropic donations from Dr. James B. Johnson  
478 and from members of the Buck Institute Impact Circle. Dr. Johnson assisted with  
479 conceptualization of the study and reviewed this manuscript but has no further role in study  
480 design, management, data collection, analysis, interpretation of data, decision to submit  
481 publications, or writing of publications. The Buck Institute Impact Circle had no role in  
482 conceptualization, study design, management, data collection, analysis, interpretation of data,  
483 decision to submit publications, review, or writing of publications.

484 Dr. Newman's participation in the study was supported by Buck Institute institutional funds.  
485 Dr. Brianna Stubbs' participation in the study was supported by the NIH (NIA) under award  
486 number K01AG078125.

487 The KE intervention was provided gratis by BHB Therapeutics Ltd (Ireland). BHB  
488 Therapeutics also arranged for manufacture of the matched placebo, paid for by study funds.  
489 BHB Therapeutics (Ireland) markets formulated KE beverages to consumers. BHB  
490 Therapeutics (Ireland) provided no funding for the study, and had no role in the design,  
491 management, data collection, analysis, interpretation of data, decision to submit publications,  
492 or writing of publications.

493 **Author Declarations and Conflict Management:**

494 The Buck Institute holds shares in BHB Therapeutics (Ireland) and Selah Therapeutics. B.J.S.  
495 has stock in H.V.M.N Inc, and stock options in Selah Therapeutics Ltd, BHB Therapeutics  
496 (Ireland) Ltd., and Juvenescence Ltd. J.C.N. has stock options in Selah Therapeutics Ltd and  
497 BHB Therapeutics (Ireland) Ltd. J.C.N and B.J.S. are inventors on patents related to the use  
498 of ketone bodies that are assigned to The Buck Institute. Individual and institutional conflict  
499 management plans were developed and approved by the Buck Institute and submitted to the  
500 reviewing IRB. Actions and decisions important to participant safety and study integrity were

501 carried out by ‘honest brokers’ with no potential financial conflict. Participant consent was  
502 obtained by licensed registered nurses (L.A and W.S.M) who have no financial conflict.  
503 Decisions on participant enrollment, continuation, and were made by independent medical  
504 officers (J.M and M.Y) unaffiliated with Buck Institute and with no financial conflict. All  
505 other authors have no conflicts to report.

506 **Author Contributions:** Conceptualization, J.C.N, B.J.S, J.B.J; methodology, J.C.N, B.J.S,  
507 J.B.J; investigation, B.J.S, E.B.S, C.S, S.R.D, S.P, W.S-M, L.A, M.Y, J.M; data curation,  
508 B.J.S, E.B.S, C.S, S.R.D, S.P, J.K; formal analysis, B.J.S, E.B.S, J.K, J.T.Y, A.F; writing—  
509 original draft preparation, B.J.S, E.B.S; writing—review and editing, all; visualization, B.J.S,  
510 E.B.S; project administration, B.J.S, J.C.N, T.G; supervision: B.J.S, T.G, J.C.N; funding  
511 acquisition, B.J.S, J.C.N, J.B.J; All authors have read and agreed to the published version of  
512 the manuscript.

513 **Data Availability Statement:** The data presented here may be available upon reasonable  
514 request from the corresponding author and in accordance with intellectual property  
515 considerations.

516

## Reference List

517

518

519 1. Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, et al.  
520 Strategies and Challenges in Clinical Trials Targeting Human Aging. *J Gerontol A Biol Sci*  
521 *Med Sci*. 2016;71(11):1424-34.

522 2. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management  
523 of frailty: opportunities, challenges, and future directions. *Lancet*. 2019;394(10206):1376-86.

524 3. Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al.  
525 Frailty in Older Adults: A Nationally Representative Profile in the United States. *J Gerontol*  
526 *A Biol Sci Med Sci*. 2015;70(11):1427-34.

527 4. Zampino M, Brennan NA, Kuo PL, Spencer RG, Fishbein KW, Simonsick EM, et al.  
528 Poor mitochondrial health and systemic inflammation? Test of a classic hypothesis in the  
529 Baltimore Longitudinal Study of Aging. *Geroscience*. 2020;42(4):1175-82.

530 5. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular  
531 disease, and frailty. *Nature reviews Cardiology*. 2018;15(9):505-22.

532 6. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging:  
533 An expanding universe. *Cell*. 2023;186(2):243-78.

534 7. Walston J, Buta B, Xue QL. Frailty Screening and Interventions: Considerations for  
535 Clinical Practice. *Clin Geriatr Med*. 2018;34(1):25-38.

536 8. Newman AB, Blackwell TL, Mau T, Cawthon PM, Coen PM, Cummings SR, et al.  
537 Vigor to Frailty As a Continuum—A New Approach in the Study of Muscle, Mobility, and  
538 Aging Cohort. *The Journals of Gerontology: Series A*. 2024;79(1).

539 9. Green CL, Lamming DW, Fontana L. Molecular mechanisms of dietary restriction  
540 promoting health and longevity. *Nat Rev Mol Cell Biol*. 2022;23(1):56-73.

541 10. Rickman AD, Williamson DA, Martin CK, Gilhooly CH, Stein RI, Bales CW, et al.  
542 The CALERIE Study: design and methods of an innovative 25% caloric restriction  
543 intervention. *Contemp Clin Trials*. 2011;32(6):874-81.

544 11. Newman JC, Verdin E. beta-Hydroxybutyrate: A Signaling Metabolite. *Annual*  
545 *review of nutrition*. 2017;37:51-76.

546 12. Roberts MN, Wallace MA, Tomilov AA, Zhou Z, Marcotte GR, Tran D, et al. A  
547 Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. *Cell Metabolism*.  
548 2017;26(3):539-46.e5.

549 13. Newman JC, Covarrubias AJ, Zhao M, Yu X, Gut P, Ng C-P, et al. Ketogenic Diet  
550 Reduces Midlife Mortality and Improves Memory in Aging Mice. *Cell metabolism*.  
551 2017;26(3):547-57.e8.

- 552 14. Crabtree CD, Blade T, Hyde PN, Buga A, Kackley ML, Sapper TN, et al. Bis  
553 Hexanoyl (R)-1,3-Butanediol, a Novel Ketogenic Ester, Acutely Increases Circulating r- and  
554 s-ss-Hydroxybutyrate Concentrations in Healthy Adults. *J Am Nutr Assoc.* 2023;42(2):169-  
555 77.
- 556 15. Stubbs BJ, Cook C, Blonquist TM, Taggart K, Beckman D, Kruger C, et al. A  
557 randomized, open-label, cross-over pilot study investigating metabolic product kinetics of the  
558 palatable novel ketone ester, bis-octanoyl (R)-1,3-butanediol, and bis-hexanoyl (R)-1,3-  
559 butanediol ingestion in healthy adults. *Toxicology Research and Application.* 2023;7.
- 560 16. Stubbs BJ, Blade T, Mills S, Thomas J, Yufei X, Nelson FR, et al. In vitro stability  
561 and in vivo pharmacokinetics of the novel ketogenic ester, bis hexanoyl (R)-1,3-butanediol.  
562 *Food Chem Toxicol.* 2021;147:111859.
- 563 17. Koutnik AP, Poff AM, Ward NP, DeBlasi JM, Soliven MA, Romero MA, et al.  
564 Ketone Bodies Attenuate Wasting in Models of Atrophy. *J Cachexia Sarcopenia Muscle.*  
565 2020.
- 566 18. Yurista SR, Matsuura TR, Sillje HHW, Nijholt KT, McDaid KS, Shewale SV, et al.  
567 Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in  
568 Preclinical Models of Heart Failure. *Circ Heart Fail.* 2021;14(1):e007684.
- 569 19. Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al.  
570 The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. *JCI Insight.*  
571 2019;4(4).
- 572 20. Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, et al. Ketogenic  
573 Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. *Cell.*  
574 2020;181(6):1263-75.e16.
- 575 21. Goldberg EL, Molony RD, Kudo E, Sidorov S, Kong Y, Dixit VD, et al. Ketogenic  
576 diet activates protective  $\gamma\delta$  T cell responses against influenza virus infection. *Sci Immunol.*  
577 2019;4(41).
- 578 22. Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of Exogenous Ketone  
579 Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis. *Adv Nutr.*  
580 2022.
- 581 23. Myette-Côté É, Caldwell HG, Ainslie PN, Clarke K, Little JP. A ketone monoester  
582 drink reduces the glycemic response to an oral glucose challenge in individuals with obesity:  
583 a randomized trial. *The American Journal of Clinical Nutrition.* 2019;110(6):1491-501.
- 584 24. Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, et al. Nutritional Ketosis  
585 Alters Fuel Preference and Thereby Endurance Performance in Athletes. *Cell Metab.*  
586 2016;24(2):256-68.

- 587 25. Poffe C, Ramaekers M, Bogaerts S, Hespel P. Bicarbonate Unlocks the Ergogenic  
588 Action of Ketone Monoester Intake in Endurance Exercise. *Med Sci Sports Exerc.*  
589 2021;53(2):431-41.
- 590 26. Evans M, Egan B. Intermittent Running and Cognitive Performance after Ketone  
591 Ester Ingestion. *Med Sci Sports Exerc.* 2018;50(11):2330-8.
- 592 27. Walsh JJ, Caldwell HG, Neudorf H, Ainslie PN, Little JP. Short-term ketone  
593 monoester supplementation improves cerebral blood flow and cognition in obesity: A  
594 randomized cross-over trial. *J Physiol.* 2021;599(21):4763-78.
- 595 28. Neudorf H, Myette-Côté É, P. Little J. The Impact of Acute Ingestion of a Ketone  
596 Monoester Drink on LPS-Stimulated NLRP3 Activation in Humans with Obesity. *Nutrients.*  
597 2020;12(3).
- 598 29. Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, et al. Acute  
599 Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. *J*  
600 *Am Soc Echocardiogr.* 2022;35(3):305-11.
- 601 30. Stubbs BJ, Alvarez-Azanedo G, Peralta S, Roa-Diaz S, Gray W, Alexander L, et al.  
602 Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group,  
603 double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via  
604 immunometabolic geroscience mechanisms (Preprint). *MedRxiv.* 2023.
- 605 31. Stubbs BJ, Stephens EB, Senadheera C, Peralta S, Roa-Diaz S, Alexander L, et al.  
606 Daily consumption of ketone ester, bis-octanoyl (R)-1,3-butanediol, is safe and tolerable in  
607 healthy older adults in a randomized, parallel arm, double-blind, placebo-controlled, pilot  
608 study. *The Journal of nutrition, health and aging.* 2024;28(9).
- 609 32. Stephens EB, Senadheera C, Roa-Diaz S, Peralta S, Alexander L, Silverman-Martin  
610 W, et al. A randomized open-label, observational study of the novel ketone ester, bis octanoyl  
611 (R)-1,3-butanediol, and its acute effect on  $\beta$ -hydroxybutyrate and glucose concentrations in  
612 healthy older adults. *medRxiv.* 2024.
- 613 33. Katz S. Assessing self-maintenance: activities of daily living, mobility, and  
614 instrumental activities of daily living. *J Am Geriatr Soc.* 1983;31(12):721-7.
- 615 34. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and  
616 Instrumental Activities of Daily Living. *The Gerontologist.* 1969;9(3 Part 1):179-86.
- 617 35. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A  
618 global clinical measure of fitness and frailty in elderly people. *CMAJ.* 2005;173(5):489-95.
- 619 36. Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce Health  
620 Care Resources. *Can Geriatr J.* 2020;23(3):210-5.

- 621 37. Borg G. Borg's perceived exertion and pain scales. Champaign, IL, US: Human  
622 Kinetics; 1998. viii, 104 p.
- 623 38. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A  
624 short physical performance battery assessing lower extremity function: association with self-  
625 reported disability and prediction of mortality and nursing home admission. *J Gerontol.*  
626 1994;49(2):M85-94.
- 627 39. Tchkonja T, Kritchevsky SB, Kuchel GA, Kirkland JL. NIA Translational  
628 Geroscience Network: An infrastructure to facilitate geroscience-guided clinical trials. *J Am*  
629 *Geriatr Soc.* 2024;72(5):1605-7.
- 630 40. Justice J, Miller JD, Newman JC, Hashmi SK, Halter J, Austad SN, et al. Frameworks  
631 for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging  
632 Processes. *J Gerontol A Biol Sci Med Sci.* 2016;71(11):1415-23.
- 633 41. Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, et al. Insulin,  
634 ketone bodies, and mitochondrial energy transduction. *FASEB J.* 1995;9(8):651-8.
- 635 42. Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N,  
636 et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake  
637 and Increases Blood Flow in Humans: A Positron Emission Tomography Study. *J Am Heart*  
638 *Assoc.* 2017;6(3):e005066.
- 639 43. Nair KS, Welle SL, Halliday D, Campbell RG. Effect of beta-hydroxybutyrate on  
640 whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in  
641 humans. *J Clin Invest.* 1988;82(1):198-205.
- 642 44. Thomsen HH, Rittig N, Johannsen M, Moller AB, Jorgensen JO, Jessen N, et al.  
643 Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling  
644 during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies. *Am J*  
645 *Clin Nutr.* 2018;108(4):857-67.
- 646 45. Poffe C, Ramaekers M, Van Thienen R, Hespel P. Ketone ester supplementation  
647 blunts overreaching symptoms during endurance training overload. *J Physiol.*  
648 2019;597(12):3009-27.
- 649 46. Vandoorne T, De Smet S, Ramaekers M, Van Thienen R, De Bock K, Clarke K, et al.  
650 Intake of a Ketone Ester Drink during Recovery from Exercise Promotes mTORC1 Signaling  
651 but Not Glycogen Resynthesis in Human Muscle. *Front Physiol.* 2017;8:310.
- 652 47. Oktaviana J, Zanker J, Vogrin S, Duque G. The effect of protein supplements on  
653 functional frailty in older persons: A systematic review and meta-analysis. *Arch Gerontol*  
654 *Geriatr.* 2020;86.
- 655 48. Vieira AF, Santos JS, Costa RR, Cadore EL, Macedo RCO. Effects of Protein  
656 Supplementation Associated with Resistance Training on Body Composition and Muscle



- 657 Strength in Older Adults: A Systematic Review of Systematic Reviews with Meta-analyses.  
658 Sports Medicine. 2022;52(10):2511-22.
- 659 49. Cermak NM, Res PT, de Groot LC, Saris WHM, van Loon LJC. Protein  
660 supplementation augments the adaptive response of skeletal muscle to resistance-type  
661 exercise training: a meta-analysis. The American Journal of Clinical Nutrition.  
662 2012;96(6):1454-64.
- 663 50. Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al.  
664 Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of  
665 ageing. Nat Rev Drug Discov. 2020.
- 666 51. Svart M, Gormsen LC, Hansen J, Zeidler D, Gejl M, Vang K, et al. Regional cerebral  
667 effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake,  
668 unchanged oxygen consumption and increased blood flow by positron emission tomography.  
669 A randomized, controlled trial. PLoS One. 2018;13(2):e0190556.
- 670 52. Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, et al.  
671 Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the  
672 action of the ketone body beta-hydroxybutyrate. eLife. 2016;5.
- 673 53. Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, et al. A  
674 ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT.  
675 Alzheimer's & dementia : the journal of the Alzheimer's Association. 2021;17(3):543-52.
- 676 54. Harinath G, Zalzal S, Nyquist A, Wouters M, Isman A, Moel M, et al. The role of  
677 quality of life data as an endpoint for collecting real-world evidence within geroscience  
678 clinical trials. Ageing Res Rev. 2024;97.
- 679 55. Nielsen R, Moller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al.  
680 Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic  
681 Heart Failure Patients. Circulation. 2019;139(18):2129-41.
- 682 56. Berg-Hansen K, Gopalasingam N, Christensen KH, Ladefoged B, Andersen MJ,  
683 Poulsen SH, et al. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With  
684 Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind  
685 Trial. Circulation. 2024;149(19):1474-89.
- 686 57. Robberechts R, Albouy G, Hespel P, Poffé C. Exogenous Ketosis Improves Sleep  
687 Efficiency and Counteracts the Decline in REM Sleep after Strenuous Exercise. Medicine &  
688 Science in Sports & Exercise. 2023;55(11):2064-74.
- 689 58. Ramar K, Malhotra RK, Carden KA, Martin JL, Abbasi-Feinberg F, Aurora RN, et al.  
690 Sleep is essential to health: an American Academy of Sleep Medicine position statement. J  
691 Clin Sleep Med. 2021;17(10):2115-9.

- 692 59. Li J, Vitiello MV, Gooneratne NS. Sleep in Normal Aging. *Sleep Med Clin.*  
693 2018;13(1):1-11.
- 694 60. Rolland Y, Sierra F, Ferrucci L, Barzilai N, De Cabo R, Mannick J, et al. Challenges  
695 in developing Geroscience trials. *Nature Communications.* 2023;14(1).
- 696 61. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, et al.  
697 Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-  
698 Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future  
699 Directions. *Circulation.* 2020;141(10):843-62.
- 700 62. Šagát P, Kalčík Z, Bartík P, Šiška L, Štefan L. A Simple Equation to Estimate  
701 Maximal Oxygen Uptake in Older Adults Using the 6 min Walk Test, Sex, Age and Body  
702 Mass Index. *Journal of Clinical Medicine.* 2023;12(13).  
703  
704

## 705 **Supplementary Information – Full Inclusion and Exclusion Criteria**

### 706 *Inclusion Criteria*

- 707 1. Subject is greater than or equal to 65 years of age, inclusive at Visit 1.
- 708 2. Subject has a BMI 18.5-34.9 kg/m<sup>2</sup> (inclusive) at Visit 1.
- 709 3. Subject is willing and able to comply with all study procedures including randomization  
710 into any of the experimental groups, maintenance of habitual dietary intake, exercise and  
711 medication and supplement use, blood draws and the following prior to test visits: fasting  
712 (≥10 h; water only), no alcohol (≥ 10 h), no cannabis products (≥10 h) and no exercise (≥  
713 10 h).
- 714 4. Subject has no health conditions that would prevent them from fulfilling the study  
715 requirements as judged by the Clinical Investigator on the basis of medical history and  
716 routine laboratory test results.
- 717 5. Subject understands the study procedures and signs forms providing informed consent to  
718 participate in the study.

### 719 *Exclusion Criteria*

- 720 2. Subject is non ambulatory
- 721 3. Subject has a CSHA clinical frailty score > 5
- 722 4. Subject requires assistance with any activity of daily living, excluding continence
- 723 5. Subject lives in an institutional setting (skilled nursing facility or residential care facility  
724 for the elderly).
- 725 6. Subject is a female who has not passed menopause.
- 726 7. Subject is unable to converse in English
- 727 8. Subject is unable to provide informed consent due to cognitive impairment or insufficient  
728 English language comprehension
- 729 9. Subject has been hospitalized within 30 days of Visit 1, 2 or 3.
- 730 10. Subject has an abnormal laboratory test result(s) of clinical importance, indicating  
731 unstable chronic disease of major organ dysfunction, at Visit 1, at the discretion of the  
732 Medical Officer. One re-test will be allowed on a separate day prior to Visit 2, for  
733 subjects with abnormal laboratory test results.
- 734 11. Subject has a history or presence of uncontrolled and/or clinically active pulmonary,  
735 cardiac (e.g. ≥ New York Heart Association class III), hepatic, renal, endocrine  
736 (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or  
737 Parkinson's diseases), psychiatric (including unstable depression and/or anxiety  
738 disorders) or biliary disorders. Stable chronic disease is not an exclusion criterion unless  
739 specified.
- 740 12. Subject has a clinically important gastrointestinal condition that would potentially  
741 interfere with the evaluation of the study beverage [e.g., inflammatory bowel disease,  
742 irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the  
743 Clinical Investigator), history of frequent diarrhea, history of surgery for weight loss,  
744 gastroparesis, systemic disease that might affect gut motility according to the  
745 Investigator, reflux requiring daily medication, history of gastrointestinal ulcers or  
746 bleeding, and/or clinically important lactose intolerance].
- 747 13. Subject has a history of alcohol or substance abuse.
- 748 14. Subject is consistently using prescriptive or over-the counter medications where alcohol  
749 is a contraindication at the discretion of the Investigator.

- 750 15. Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the  
751 study beverages, including soy and milk protein.
- 752 16. Subject has uncontrolled hypertension (systolic blood pressure  $\geq 140$  mm Hg or diastolic  
753 blood pressure  $\geq 90$  mm Hg) as defined by the blood pressure measured at Visit 1. One re-  
754 test will be allowed on a separate day before Visit 2, for subjects with abnormal blood  
755 pressure.
- 756 17. Subject is undergoing treatment or active surveillance for cancer, or has been diagnosed  
757 with cancer in the prior two years, except for non-melanoma skin cancer.
- 758 18. Subject has recently used antibiotics within 30 days of Visit 1, 2 or 3.
- 759 19. Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating,  
760 Atkins diet, vegan, very high protein/low carbohydrate or has used weight-loss  
761 medications (including over-the-counter medications and/or supplements) or programs  
762 within 30 days of Visit 1, 2 or 3.
- 763 20. Subject has used medications (over-the-counter or prescription) known to influence  
764 gastrointestinal function including, but not limited to, opioids, weight loss medications,  
765 antidiarrheals, and antispasmodics) within 30 days of Visit 1, 2 or 3.
- 766 21. Subject has used ketone supplements (ketone salts or esters, and medium chain  
767 triglycerides [MCT]) within 30 days of Visit 1, 2 or 3.
- 768 22. Subject has unstable use of thyroid, antihypertensive, antidepressant, or statin  
769 medications within 30 days of Visit 1, 2 or 3.
- 770 23. Subject has a condition the Clinical Investigator believes would interfere with their ability  
771 to provide informed consent, comply with the study protocol, which might confound the  
772 interpretation of the study results, or put the subject at undue risk.
- 773 24. Subject works nights or shifts that means it is not possible to maintain a consistent meal  
774 schedule during the study.
- 775 25. Subject is not permitted to visit the Buck Institute campus, for example due to inability to  
776 confirm COVID-19 vaccination status.
- 777 26. Subject does not have a Bluetooth enabled smartphone.
- 778 27. Subject does not have access to the internet

779 *Excluded Medications/Supplements/Products*


780 Use of thyroid hormone therapy, statins, antihypertensives, antidepressants, constipation  
781 medications should be **stable** for the 30 days prior to Visit 1, 2 or 3. Additionally, use of any  
782 antibiotic therapy is not permitted within 30 days of Visit 1, 2 or 3 and throughout the study  
783 period. Subjects should not use opioids, weight loss medications, antidiarrheals,  
784 antispasmodics, ketone supplements (including MCT oil), or other medications (over-the-  
785 counter or prescription) or dietary supplements known to alter gastrointestinal function within  
786 30 days of Visit 1, 2 or 3 and throughout the study period, with the exception of stable use of  
787 constipation medications and supplements.

788

789 Should a subject require any of these medications or supplements, the study staff should  
790 consult with the Investigator to discuss the subject's continued participation in the trial. At  
791 the discretion of the Medical Officer in consultation with the Investigator, subjects may  
792 suspend consumption of the Study Product and completion of the Study Log for up to 10  
793 days and re-start the protocol at the point of suspension.

794

795 **Supplementary Figure 1**



796

797

798 **Supplementary Table 1: Study participant characteristics**

	<i>Statistic/Group</i>	<i>Total Enrolled (n=30)</i>	<i>KE (n=15)</i>	<i>PLA (n=15)</i>
Sex	Female	15 (50%)	8 (53.3%)	7 (46.7%)
	Male	15 (50%)	7 (46.7%)	8 (53.3%)
Age (years)	Mean (SD)	76.5 (6.4)	75.2 (5.6)	77.9 (7.0)
	Median (min, max)	75.8 (65.1, 89.8)	75.1 (65.1, 87.3)	76.4 (67.5, 89.8)
Katz ADL Score	Mean (SD)	5.9 (0.3)	5.9 (0.3)	5.9 (0.3)
Lawton IADL Score	Mean (SD)	8 (0)	8 (0)	8 (0)
CSHA Frailty Score	Mean (SD)	1.2 (0.5)	1.3 (0.6)	1.2 (0.4)
Ethnicity	Hispanic/Latino	2 (6.7%)	1 (6.7%)	1 (6.7%)
	Not Hispanic/Latino	28 (93.3%)	14 (93.3%)	14 (93.3%)
	Prefer not to say	0 (0%)	0 (0%)	0 (0%)
Race	American Indian/Alaskan Native	0 (0%)	0 (0%)	0 (0%)
	Asian	1 (3.3%)	1 (6.7%)	0 (0%)
	Black/African American	0 (0%)	0 (0%)	0 (0%)
	Hispanic, Latinx, or Spanish Origin	2 (6.7%)	1 (6.7%)	1 (6.7%)
	Native Hawaiian or Other Pacific Islander	0 (0%)	0 (0%)	0 (0%)
	Prefer not to say	0 (0%)	0 (0%)	0 (0%)
	Two or more races	0 (0%)	0 (0%)	0 (0%)
	Unknown	0 (0%)	0 (0%)	0 (0%)
	White	27 (90%)	13 (86.7%)	14 (93.3%)
	Weight (kg)	Mean (SD)	72.9 (15.8)	70.3 (15.0)
Median (min, max)		72.1 (47.8, 101.3)	70.3 (47.8, 101.3)	76.4 (50.5, 99.7)
Height (cm)	Mean (SD)	168.0 (10.8)	166.2 (11.0)	169.8 (10.6)
	Median (min, max)	168.8 (150.0, 189.0)	166.0 (150.0, 188.0)	169.0 (153.0, 189.0)
BMI (kg/m <sup>2</sup> )	Mean (SD)	25.2 (3.0)	24.5 (2.2)	25.9 (3.6)
	Median (min, max)	25.8 (19.9, 32.7)	25.0 (21.0, 28.0)	26.7 (19.9, 32.7)
Waist Circumference (cm)	Mean (SD)	91.2 (12.2)	88.5 (12.5)	94.0 (11.6)
	Median (min, max)	92.0 (66.5, 118.0)	88.0 (66.5, 118.0)	98.0 (75.5, 113.0)

799 Description of characteristics of randomized study participants. Data represents all  
800 individuals' values obtained at their screening visit.

801 **Abbreviations:** BMI, body mass index; KE, ketone ester; max, maximum; min, minimum;  
802 PLA, placebo; SD, standard deviations.

803  
804

805

---

	KE	PLA
BO-BD (g)	25	0
Energy (kcal)	240	246
Carbohydrate (g)	2	2
Fat (g)	0.5	25
Protein (g)	2	2

---

806 **Supplementary Table 2. Nutritional Information.** Nutritional information for the KE and  
807 PLA beverages.

808 **Abbreviations:** BO-BD, bis-octanoyl (R)-1,3 butanediol; KE, ketone ester; PLA, placebo

809